Elsaid Ossama, Tecson Kristen M, Khan Hafiza, Assar Manish D
Division of Cardiology, Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas.
Baylor Heart and Vascular Institute, Baylor Scott & White Research Institute, Dallas, Texas.
Proc (Bayl Univ Med Cent). 2021 Jan 22;34(3):378-379. doi: 10.1080/08998280.2020.1871266.
Flecainide is an antiarrhythmic agent indicated for patients with supraventricular arrhythmias without ischemic or structural heart disease. Flecainide toxicity is a rare condition in which patients may present with bradycardia, widening of QRS, PR prolongation, ventricular tachycardia, syncope, malaise, dizziness, visual disturbance, nausea, vomiting, and/or lethargy. It carries an associated mortality rate of approximately 10%. Herein, we describe the course of a patient who experienced flecainide toxicity in the setting of renal and liver failure.
氟卡尼是一种抗心律失常药物，适用于无缺血性或结构性心脏病的室上性心律失常患者。氟卡尼中毒是一种罕见的情况，患者可能出现心动过缓、QRS波增宽、PR间期延长、室性心动过速、晕厥、不适、头晕、视觉障碍、恶心、呕吐和/或嗜睡。其相关死亡率约为10%。在此，我们描述了一名在肾衰竭和肝衰竭情况下发生氟卡尼中毒的患者的病程。
